The prodrug platin-A: Simultaneous release of cisplatin and aspirin

Rakesh K. Pathak, Sean Marrache, Joshua H. Choi, Trenton B. Berding, Shanta Dhar

Research output: Contribution to journalArticle

147 Scopus citations

Abstract

Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.

Original languageEnglish (US)
Pages (from-to)1963-1967
Number of pages5
JournalAngewandte Chemie - International Edition
Volume53
Issue number7
DOIs
StatePublished - Feb 10 2014
Externally publishedYes

Keywords

  • antitumor agents
  • drug design
  • inflammation
  • platinum
  • prodrugs

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)

Fingerprint Dive into the research topics of 'The prodrug platin-A: Simultaneous release of cisplatin and aspirin'. Together they form a unique fingerprint.

  • Cite this